k141_48487_2	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	26.4	686	673	641	2.64e-46	173
k141_48487_3	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	52.2	251	256	255	3.94e-88	261
k141_48487_3	SARG|gi|895872463|ref|WP_048979698.1|	41.8	220	256	646	2.09e-54	184
k141_48487_3	SARG|gi|922960663|ref|WP_053388845.1|	41.4	220	256	648	2.14e-54	184
k141_48487_3	SARG|gi|695731723|ref|WP_032658224.1|	41.8	220	256	646	2.90e-54	184
k141_48487_3	SARG|gi|835749851|ref|WP_047648187.1|	41.8	220	256	646	2.90e-54	184
k141_48487_3	SARG|gi|697052471|ref|WP_033145077.1|	41.8	220	256	646	2.90e-54	184
k141_48487_3	SARG|gi|695722592|ref|WP_032649220.1|	41.8	220	256	646	2.90e-54	184
k141_48487_3	SARG|gi|829942568|ref|WP_047368199.1|	42.3	220	256	646	2.90e-54	184
k141_48487_3	SARG|gi|895868403|ref|WP_048976842.1|	41.8	220	256	646	2.90e-54	184
k141_48487_3	SARG|gi|658546960|ref|WP_029739484.1|	41.8	220	256	646	2.90e-54	184
k141_48487_7	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	52.3	220	228	223	2.31e-82	244
k141_48487_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	30.0	227	228	232	1.65e-35	124
k141_48487_7	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	29.7	236	228	239	2.35e-33	119
k141_48487_7	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.5	217	228	219	2.40e-31	113
k141_48487_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.4	218	228	228	4.20e-31	113
k141_48487_7	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.5	217	228	219	4.75e-31	112
k141_48487_7	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.5	217	228	220	4.87e-31	112
k141_48487_7	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.5	217	228	220	6.84e-31	112
k141_48487_7	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.0	217	228	220	1.47e-29	108
k141_48487_7	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	26.9	219	228	225	6.91e-28	104
k141_48487_15	SARG|Q52360	25.9	459	532	641	1.21e-31	128
k141_48487_15	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.1	459	532	654	2.44e-30	124
k141_48487_15	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	25.1	459	532	670	2.58e-30	124
k141_48487_15	SARG|AAB51122	25.1	459	532	670	2.58e-30	124
k141_48487_15	SARG|Q08425	24.8	459	532	641	7.51e-30	122
k141_48487_15	SARG|P70882	25.5	459	532	641	7.51e-30	122
k141_48487_15	SARG|BAD46890	25.5	459	532	657	7.97e-30	122
k141_48487_15	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	24.8	459	532	657	7.97e-30	122
k141_48487_15	SARG|Z21523.gene.p01	24.8	459	532	657	7.97e-30	122
k141_48487_15	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.4	464	532	641	4.37e-29	120
k141_93607_18	SARG|gb|AAC75314.1|ARO:3003578|pmrF	32.3	96	338	322	6.53e-08	52.4
k141_111016_2	SARG|DQ018711.1.gene4.p01	32.0	275	324	322	1.21e-30	117
k141_111016_2	SARG|gi|737310392|ref|WP_035293250.1|	31.6	275	324	323	6.34e-29	112
k141_111016_2	SARG|gi|738848198|ref|WP_036737307.1|	30.9	275	324	323	2.30e-27	108
k141_111016_2	SARG|FJ349556.1.gene5.p01	32.7	275	324	326	8.89e-27	106
k141_7171_5	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	45.8	995	997	1033	0.0	912
k141_7171_5	SARG|gb|AEY83581|ARO:3000510|mupB	45.8	995	997	1033	0.0	912
k141_7171_5	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	46.1	982	997	1024	3.12e-320	910
k141_7171_5	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	46.1	982	997	1024	3.12e-320	910
k141_7171_5	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	45.9	982	997	1024	2.65e-318	905
k141_7171_5	SARG|gb|CAA53189|ARO:3000521|mupA	45.9	982	997	1024	2.65e-318	905
k141_7171_5	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	35.6	1063	997	1107	1.39e-209	629
k141_7171_5	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	35.6	1063	997	1107	1.39e-209	629
k141_41666_2	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.7	292	457	370	8.32e-28	112
k141_41666_2	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.2	254	457	381	2.99e-26	108
k141_41666_2	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.2	254	457	381	2.99e-26	108
k141_41666_2	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.1	303	457	365	1.13e-25	106
k141_41666_2	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.8	254	457	381	1.40e-25	106
k141_41666_2	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.8	254	457	381	1.40e-25	106
k141_41666_2	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.4	254	457	381	3.53e-25	105
k141_41666_2	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	254	457	381	3.53e-25	105
k141_41666_2	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.6	254	457	381	4.80e-25	105
k141_41666_2	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.6	254	457	381	4.80e-25	105
k141_17445_7	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	30.8	247	322	314	6.56e-35	128
k141_17445_7	SARG|DQ018711.1.gene4.p01	32.3	257	322	322	4.09e-34	126
k141_17445_7	SARG|AF155139.2.gene6.p01	32.6	261	322	322	5.71e-34	125
k141_17445_7	SARG|gi|749574782|ref|WP_040203616.1|	32.3	257	322	323	8.12e-34	125
k141_17445_7	SARG|gi|746609237|ref|WP_039635344.1|	32.8	256	322	322	1.11e-33	125
k141_17445_7	SARG|gi|738848198|ref|WP_036737307.1|	32.3	257	322	323	8.29e-33	122
k141_17445_7	SARG|gi|737310392|ref|WP_035293250.1|	31.5	257	322	323	3.12e-32	121
k141_17445_7	SARG|gi|740152780|ref|WP_037997109.1|	29.1	316	322	322	1.60e-31	119
k141_17445_7	SARG|NP_878015	29.8	262	322	322	2.22e-31	119
k141_17445_7	SARG|CAB61228	30.7	257	322	322	1.61e-30	116
k141_34884_23	SARG|gb|AAC74000.1|ARO:3003950|msbA	26.4	500	566	582	6.27e-46	169
k141_34884_23	SARG|gi|505420018|ref|WP_015607120.1|	25.4	560	566	603	1.03e-44	166
k141_34884_23	SARG|gi|695842130|ref|WP_032755430.1|	25.4	560	566	603	1.41e-44	166
k141_34884_23	SARG|gi|496018010|ref|WP_008742581.1|	25.4	551	566	623	1.78e-44	166
k141_34884_23	SARG|gi|516795764|ref|WP_018105258.1|	26.1	556	566	601	3.52e-44	164
k141_34884_23	SARG|gi|517347347|ref|WP_018522839.1|	26.0	558	566	601	9.00e-44	163
k141_34884_23	SARG|gi|860594225|ref|WP_048475168.1|	25.1	549	566	620	1.53e-43	163
k141_34884_23	SARG|gi|1033217078|gb|OAR27197.1|	25.2	555	566	601	1.68e-43	162
k141_34884_23	SARG|gi|639148059|ref|WP_024490169.1|	27.8	496	566	602	1.70e-43	162
k141_34884_23	SARG|gi|817122037|ref|WP_046494699.1|	26.4	493	566	613	6.73e-43	161
k141_41785_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	37.3	241	612	582	6.03e-45	167
k141_41785_2	SARG|gi|1045390184|ref|WP_065479071.1|	37.3	249	612	605	4.34e-37	145
k141_41785_2	SARG|gi|928900436|ref|WP_053931243.1|	37.1	229	612	600	5.61e-37	144
k141_41785_2	SARG|gi|664579989|ref|WP_031094015.1|	37.1	229	612	601	5.66e-37	144
k141_41785_2	SARG|gi|662754041|ref|WP_030125200.1|	37.4	230	612	601	1.40e-36	143
k141_41785_2	SARG|gi|664100597|ref|WP_030638327.1|	37.4	230	612	601	1.40e-36	143
k141_41785_2	SARG|gi|505389066|ref|WP_015576168.1|	37.4	230	612	601	1.40e-36	143
k141_41785_2	SARG|gi|503923650|ref|WP_014157644.1|	37.4	230	612	601	1.40e-36	143
k141_41785_2	SARG|gi|926400371|ref|WP_053728483.1|	38.0	229	612	603	1.42e-36	143
k141_41785_2	SARG|gi|695865802|ref|WP_032778631.1|	37.1	229	612	605	1.95e-36	143
k141_41785_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	37.1	240	632	582	7.87e-45	167
k141_41785_3	SARG|gi|739906046|ref|WP_037756452.1|	37.1	237	632	620	8.17e-42	159
k141_41785_3	SARG|gi|516574297|ref|WP_017949361.1|	37.1	237	632	620	1.11e-41	159
k141_41785_3	SARG|AF170880.4.gene1.p01	36.7	237	632	615	1.43e-41	158
k141_41785_3	SARG|gi|926351744|ref|WP_053683383.1|	36.8	239	632	648	1.46e-41	159
k141_41785_3	SARG|gi|664100597|ref|WP_030638327.1|	35.9	237	632	601	1.67e-41	158
k141_41785_3	SARG|gi|505389066|ref|WP_015576168.1|	35.9	237	632	601	1.67e-41	158
k141_41785_3	SARG|gi|503923650|ref|WP_014157644.1|	35.9	237	632	601	1.67e-41	158
k141_41785_3	SARG|gi|664352659|ref|WP_030880307.1|	35.9	237	632	601	2.26e-41	157
k141_41785_3	SARG|gi|558888514|ref|WP_023543283.1|	36.3	237	632	615	2.63e-41	157
k141_142272_4	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.1	528	638	655	7.46e-126	385
k141_142272_4	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.9	528	638	655	1.05e-125	385
k141_142272_4	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.9	528	638	655	1.05e-125	385
k141_142272_4	SARG|gb|AKA86814|ARO:3003746|optrA	40.9	528	638	655	1.05e-125	385
k141_142272_4	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.1	528	638	655	2.09e-125	384
k141_142272_4	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.3	528	638	655	2.94e-125	384
k141_142272_4	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.9	528	638	655	4.14e-125	383
k141_142272_4	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.9	528	638	655	5.83e-125	383
k141_142272_4	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.9	528	638	655	5.83e-125	383
k141_142272_4	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.9	528	638	655	5.83e-125	383
k141_135337_4	SARG|YP_254125	31.5	200	213	291	1.46e-21	89.0
k141_135337_4	SARG|NP_645462	33.0	191	213	291	1.46e-21	89.0
k141_135337_4	SARG|ZP_04060511	33.3	192	213	289	2.73e-21	88.2
k141_135337_4	SARG|A8YZV4	32.5	191	213	291	5.41e-21	87.4
k141_135337_4	SARG|YP_040163	32.5	191	213	291	5.41e-21	87.4
k141_135337_4	SARG|ZP_03564086	32.5	191	213	291	5.41e-21	87.4
k141_135337_4	SARG|YP_416126	32.5	191	213	291	1.04e-20	86.7
k141_135337_4	SARG|P67390	32.5	191	213	291	1.04e-20	86.7
k141_135337_4	SARG|YP_185622	32.5	191	213	291	1.45e-20	86.3
k141_135337_4	SARG|NP_764009	32.3	189	213	290	3.81e-20	85.1
k141_145694_16	SARG|gi|542061059|gb|ERI11611.1|	25.7	226	503	316	1.34e-19	88.6
k141_145694_16	SARG|P42332	25.1	223	503	306	7.09e-19	86.3
k141_145694_16	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	25.1	223	503	306	7.09e-19	86.3
k141_145694_16	SARG|gi|510143239|gb|AGN36970.1|	25.1	223	503	313	7.79e-19	86.3
k141_145694_16	SARG|ABB80128	25.1	223	503	306	9.57e-19	85.9
k141_145694_16	SARG|YP_001373621	24.7	235	503	318	1.51e-18	85.5
k141_145694_16	SARG|AAD21213	25.1	223	503	306	2.35e-18	84.7
k141_145694_16	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.5	219	503	664	3.87e-14	73.9
k141_145694_16	SARG|gi|751930065|ref|WP_041144773.1|	27.3	205	503	648	1.55e-13	72.0
k141_145694_16	SARG|gb|CDO61516.1|ARO:3003949|efrB	24.5	184	503	362	5.20e-11	63.2
k141_145694_18	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	21.9	137	535	228	1.03e-06	48.9
k141_66260_3	ResF|penA_1_AF515059_1	28.3	523	578	581	1.75e-44	165
k141_66260_3	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	23.9	616	578	633	8.18e-23	101
k141_87009_14	SARG|gi|985522333|ref|WP_060811962.1|	37.3	284	330	323	1.02e-54	180
k141_87009_14	SARG|gi|498515089|ref|WP_010815296.1|	37.0	284	330	323	5.64e-54	178
k141_87009_14	SARG|Q47748	37.3	284	330	323	5.64e-54	178
k141_87009_14	SARG|gi|740152780|ref|WP_037997109.1|	34.5	316	330	322	1.09e-53	177
k141_87009_14	SARG|gb|AAB05626.1|ARO:3002943|vanHB	37.3	284	330	323	1.12e-53	177
k141_87009_14	SARG|YP_002333394	37.0	284	330	323	1.57e-53	177
k141_87009_14	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	37.0	284	330	323	1.57e-53	177
k141_87009_14	SARG|AF310956.2.gene5.p01	37.0	284	330	323	2.21e-53	177
k141_87009_14	SARG|NP_878015	32.9	316	330	322	1.19e-52	175
k141_87009_14	SARG|DQ018711.1.gene4.p01	36.3	284	330	322	2.35e-52	174
k141_87009_31	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.9	173	208	885	5.28e-17	77.8
k141_66310_3	SARG|gi|664556405|ref|WP_031071225.1|	30.3	577	579	602	1.05e-92	295
k141_66310_3	SARG|gi|1045390184|ref|WP_065479071.1|	29.8	573	579	605	1.14e-92	295
k141_66310_3	SARG|gi|664042835|ref|WP_030582300.1|	30.3	577	579	604	3.06e-92	294
k141_66310_3	SARG|gi|496018010|ref|WP_008742581.1|	30.3	577	579	623	3.51e-92	295
k141_66310_3	SARG|gi|695865802|ref|WP_032778631.1|	29.8	573	579	605	8.68e-92	293
k141_66310_3	SARG|gi|926376632|ref|WP_053705806.1|	30.3	577	579	620	8.99e-92	293
k141_66310_3	SARG|gi|764446018|ref|WP_044369325.1|	29.7	573	579	605	1.71e-91	292
k141_66310_3	SARG|gi|799286378|ref|WP_045936958.1|	30.3	577	579	620	1.77e-91	293
k141_66310_3	SARG|gi|926294973|ref|WP_053631154.1|	30.3	577	579	620	1.77e-91	293
k141_66310_3	SARG|gi|662129758|ref|WP_030081404.1|	29.8	573	579	605	2.40e-91	292
k141_132167_2	SARG|gb|ANZ79476.1|ARO:3003908|Erm(47)	30.1	266	288	246	1.30e-26	103
k141_132167_2	SARG|L22689.1.gene1.p01	31.2	250	288	257	4.53e-24	97.1
k141_132167_2	NCBI|WP_011861426.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.4	191	288	245	9.64e-23	93.2
k141_132167_2	megares|MEG_2803|Drugs|MLS|23S_rRNA_methyltransferases|ERMB_1	30.9	191	288	237	2.21e-22	92.0
k141_132167_2	SARG|gi|446961539|ref|WP_001038795.1|	30.9	191	288	245	2.58e-22	92.0
k141_132167_2	NCBI|WP_063844619.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	30.9	191	288	245	2.58e-22	92.0
k141_132167_2	NCBI|WP_063844850.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	30.9	191	288	248	2.73e-22	92.0
k141_132167_2	NCBI|WP_011018369.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	30.9	191	288	250	2.84e-22	92.0
k141_132167_2	megares|MEG_2806|Drugs|MLS|23S_rRNA_methyltransferases|ERMB_1	30.9	191	288	250	2.84e-22	92.0
k141_132167_2	SARG|YP_001836040	30.9	191	288	261	3.46e-22	92.0
k141_132167_28	SARG|gb|WP_104671188.1|ARO:3003948|efrA	30.1	239	547	575	4.27e-22	99.0
k141_132167_28	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.0	238	547	664	5.15e-21	95.9
k141_132167_28	SARG|gb|AAK76136.1|ARO:3000025|patB	27.7	238	547	588	7.70e-21	95.1
k141_132167_28	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.5	200	547	255	9.61e-21	90.9
k141_132167_28	SARG|U82085.gene.p01	22.9	545	547	552	1.12e-17	85.1
k141_132167_28	SARG|gb|ABX00624.1|ARO:3002881|lmrC	23.4	569	547	550	1.42e-16	81.6
k141_132167_28	SARG|gi|921979807|ref|WP_053271336.1|	28.7	202	547	648	1.71e-16	81.6
k141_132167_28	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	26.5	400	547	522	3.08e-16	80.5
k141_132167_28	SARG|YP_002332257	26.5	400	547	522	3.08e-16	80.5
k141_132167_28	NCBI|WP_063856937.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	27.1	413	547	522	5.42e-16	79.7
k141_111493_4	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	527	545	655	2.74e-71	239
k141_111493_4	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	527	545	655	3.82e-71	239
k141_111493_4	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	527	545	655	3.82e-71	239
k141_111493_4	SARG|gb|AKA86814|ARO:3003746|optrA	30.4	527	545	655	3.82e-71	239
k141_111493_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	527	545	655	1.03e-70	238
k141_111493_4	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	527	545	655	1.03e-70	238
k141_111493_4	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	527	545	655	1.03e-70	238
k141_111493_4	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	527	545	655	1.03e-70	238
k141_111493_4	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	527	545	655	1.44e-70	237
k141_111493_4	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	527	545	655	1.44e-70	237
k141_118464_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	45.7	348	345	648	4.30e-87	274
k141_118464_1	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	31.5	257	345	552	1.08e-29	118
k141_118464_1	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	32.6	230	345	524	1.69e-29	117
k141_118464_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	209	345	655	2.18e-29	117
k141_118464_1	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	209	345	655	2.18e-29	117
k141_118464_1	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	209	345	655	1.83e-28	115
k141_118464_1	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	31.3	230	345	522	2.01e-28	114
k141_118464_1	SARG|DQ823382.1.gene1.p01	31.3	230	345	522	2.01e-28	114
k141_118464_1	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	31.3	230	345	522	2.01e-28	114
k141_118464_1	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	31.3	230	345	522	2.01e-28	114
k141_156463_3	SARG|CAX85496	23.9	665	691	639	1.35e-41	159
k141_156463_3	SARG|gi|104303742|gb|ABF72138.1|	23.9	665	691	639	1.82e-41	159
k141_156463_3	SARG|AAY62597	23.4	655	691	639	2.47e-41	159
k141_156463_3	SARG|gi|168258996|gb|ACA23181.1|	23.6	657	691	639	3.33e-41	158
k141_156463_3	SARG|gi|1028100281|ref|WP_063856416.1|	23.6	657	691	639	3.33e-41	158
k141_156463_3	SARG|ACA23195	23.6	657	691	639	3.33e-41	158
k141_156463_3	SARG|ACA23187	23.9	665	691	639	3.33e-41	158
k141_156463_3	SARG|AJ222769.gene.p01	23.6	657	691	639	4.50e-41	158
k141_156463_3	SARG|gi|254967129|gb|ACT97610.1|	23.6	657	691	639	6.08e-41	157
k141_156463_3	SARG|ABN80187	24.0	666	691	640	6.14e-41	157
k141_132484_1	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.2	231	321	356	3.30e-25	102
k141_132484_1	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.6	233	321	355	3.05e-24	100
k141_132484_1	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.6	233	321	355	3.05e-24	100
k141_132484_1	SARG|ACM47285	29.6	233	321	363	3.38e-24	100
k141_132484_1	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.9	213	321	346	3.74e-24	99.8
k141_132484_1	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.6	233	321	355	1.50e-23	98.2
k141_132484_1	SARG|BAE96115	29.6	233	321	355	1.50e-23	98.2
k141_132484_1	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.9	231	321	356	1.52e-23	98.2
k141_132484_1	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.3	231	321	356	2.09e-23	97.8
k141_132484_1	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	30.0	190	321	209	1.07e-19	84.7
k141_76913_7	SARG|gi|1005616587|ref|WP_061695226.1|	29.7	219	506	648	3.89e-23	102
k141_76913_7	SARG|YP_001571041	29.2	219	506	648	3.89e-23	102
k141_76913_7	SARG|gi|960873409|ref|WP_058345546.1|	29.2	219	506	648	3.89e-23	102
k141_76913_7	SARG|gi|740610794|ref|WP_038396317.1|	28.8	219	506	648	1.23e-22	100
k141_76913_7	SARG|gi|555271393|ref|WP_023251561.1|	29.2	219	506	648	1.64e-22	100
k141_76913_7	SARG|gi|554922094|ref|WP_023194682.1|	29.2	219	506	648	1.64e-22	100
k141_76913_7	SARG|gi|555246906|ref|WP_023230855.1|	29.2	219	506	648	2.18e-22	99.8
k141_76913_7	SARG|YP_002044935	29.2	219	506	648	2.18e-22	99.8
k141_76913_7	SARG|gi|487407385|ref|WP_001675419.1|	29.2	219	506	648	2.18e-22	99.8
k141_76913_7	SARG|gi|835666879|ref|WP_047606339.1|	29.2	219	506	648	2.18e-22	99.8
k141_21970_2	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.7	191	498	361	9.85e-19	86.7
k141_21970_2	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.6	208	498	359	6.00e-17	81.3
k141_21970_2	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	22.7	203	498	364	6.27e-17	81.3
k141_21970_2	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	22.7	203	498	364	6.27e-17	81.3
k141_21970_2	CARD|gb|AEX49906.1|ARO:3003583|basS	19.8	217	498	477	2.28e-10	61.6
k141_21970_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.9	232	226	232	1.00e-54	174
k141_21970_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.4	231	226	231	1.11e-53	171
k141_21970_3	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.7	222	226	220	3.30e-50	162
k141_21970_3	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.3	222	226	220	3.30e-50	162
k141_21970_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.7	222	226	219	4.53e-50	161
k141_21970_3	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.7	222	226	220	4.66e-50	161
k141_21970_3	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.4	227	226	230	1.76e-49	160
k141_21970_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.7	228	226	232	1.87e-49	160
k141_21970_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.7	228	226	232	1.87e-49	160
k141_21970_3	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	37.7	236	226	239	3.23e-49	160
k141_21970_9	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.8	227	228	229	1.38e-36	127
k141_21970_9	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.9	229	228	232	2.97e-36	126
k141_21970_9	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.9	229	228	232	2.97e-36	126
k141_21970_9	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	33.6	232	228	235	1.26e-35	125
k141_21970_22	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.6	121	288	231	1.50e-08	53.1
k141_21970_22	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	27.6	134	288	252	1.43e-07	50.4
k141_21970_22	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	27.2	147	288	232	2.25e-07	49.7
k141_21970_22	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.7	120	288	220	2.75e-07	49.3
k141_21970_22	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.7	120	288	219	3.67e-07	48.9
k141_21970_22	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.7	120	288	219	3.67e-07	48.9
k141_21970_22	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.7	120	288	220	3.70e-07	48.9
k141_21970_22	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.7	120	288	220	2.22e-06	46.6
k141_21970_22	CARD|gb|ATC67679.1|ARO:3000838|arlR	27.6	87	288	219	9.76e-06	44.7
k141_59979_5	SARG|AY082011.1.gene6.p01	24.6	272	388	323	1.91e-11	63.5
k141_59979_5	SARG|gi|552942232|ref|WP_023043160.1|	24.6	272	388	323	3.42e-11	62.8
k141_60047_15	SARG|gi|923061916|ref|WP_053445667.1|	27.3	242	254	648	5.47e-20	87.8
k141_60047_15	SARG|gi|446048048|ref|WP_000125903.1|	27.7	242	254	648	1.36e-19	86.7
k141_60047_15	SARG|gi|919601241|ref|WP_052893936.1|	26.7	247	254	648	1.36e-19	86.7
k141_60047_15	SARG|gi|959109145|ref|WP_058113944.1|	27.7	242	254	648	1.36e-19	86.7
k141_60047_15	SARG|ZP_03074747	26.7	247	254	648	1.36e-19	86.7
k141_60047_15	SARG|gi|446048047|ref|WP_000125902.1|	27.7	242	254	648	1.36e-19	86.7
k141_60047_15	SARG|gi|1005616587|ref|WP_061695226.1|	26.7	247	254	648	1.84e-19	86.3
k141_60047_15	SARG|gi|959866458|ref|WP_058145168.1|	27.3	242	254	648	1.84e-19	86.3
k141_60047_15	SARG|gi|554685678|ref|WP_023185565.1|	27.7	242	254	648	1.84e-19	86.3
k141_60047_15	SARG|gi|555246906|ref|WP_023230855.1|	27.3	242	254	648	2.49e-19	85.9
k141_60047_16	SARG|gi|763407609|ref|WP_044264203.1|	25.6	238	237	648	5.90e-21	90.1
k141_60047_16	SARG|gi|968563772|ref|WP_058587854.1|	25.6	238	237	648	1.08e-20	89.4
k141_60047_16	SARG|gi|757782629|ref|WP_043001213.1|	25.6	238	237	648	1.08e-20	89.4
k141_60047_16	SARG|gi|764278838|ref|WP_044327089.1|	25.6	238	237	648	1.47e-20	89.0
k141_60047_16	SARG|gi|992390012|ref|WP_061077002.1|	25.6	238	237	648	1.99e-20	88.6
k141_60047_16	SARG|gi|754927849|ref|WP_042284850.1|	26.6	222	237	648	1.99e-20	88.6
k141_60047_16	SARG|gi|817104523|ref|WP_046477871.1|	25.6	238	237	648	3.67e-20	87.8
k141_60047_16	SARG|gi|754964360|ref|WP_042320280.1|	25.6	238	237	648	3.67e-20	87.8
k141_60047_16	SARG|YP_001176128	27.5	222	237	646	6.73e-20	87.0
k141_60047_16	SARG|gi|974588181|ref|WP_059178476.1|	27.0	222	237	646	9.12e-20	86.7
k141_45970_15	SARG|gi|803568669|ref|WP_046077412.1|	36.0	222	224	648	1.52e-37	137
k141_45970_15	SARG|gi|446110352|ref|WP_000188207.1|	36.0	222	224	648	1.52e-37	137
k141_45970_15	SARG|YP_002382193	36.0	222	224	648	1.52e-37	137
k141_45970_15	SARG|gi|803575554|ref|WP_046081557.1|	36.0	222	224	648	1.52e-37	137
k141_45970_15	SARG|gi|446110351|ref|WP_000188206.1|	36.0	222	224	648	1.52e-37	137
k141_45970_15	SARG|gi|502669352|ref|WP_012905216.1|	36.4	217	224	648	2.87e-37	136
k141_45970_15	SARG|gi|1035670474|ref|WP_064517458.1|	36.0	222	224	648	1.40e-36	134
k141_45970_15	SARG|gi|1035717981|ref|WP_064557480.1|	36.0	222	224	648	1.40e-36	134
k141_45970_15	SARG|gi|736472622|ref|WP_034494292.1|	36.0	222	224	648	1.91e-36	134
k141_45970_15	SARG|gi|1035706844|ref|WP_064548272.1|	34.7	222	224	648	2.96e-34	127
k141_101726_2	SARG|gb|ABA71733.1|ARO:3002972|vanTG	31.7	369	395	712	2.64e-59	203
k141_101726_2	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	32.8	372	395	712	2.40e-55	192
k141_101726_2	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	33.3	348	395	711	1.05e-51	182
k141_101726_9	SARG|gi|657888313|ref|WP_029592374.1|	36.8	250	262	648	4.19e-39	142
k141_101726_9	SARG|gi|639225329|ref|WP_024561799.1|	38.4	237	262	648	7.91e-39	142
k141_101726_9	SARG|gi|639218559|ref|WP_024556062.1|	38.4	237	262	648	7.91e-39	142
k141_101726_9	SARG|gi|896325272|ref|WP_049294291.1|	37.8	241	262	648	1.09e-38	141
k141_101726_9	SARG|gi|639216333|ref|WP_024554080.1|	37.3	241	262	648	2.81e-38	140
k141_101726_9	SARG|gb|AAK76137.1|ARO:3000024|patA	25.7	230	262	564	5.70e-15	73.2
k141_101726_9	SARG|gb|MBW0770001.1|ARO:3007026|salB	24.7	219	262	541	2.03e-08	53.5
k141_101726_9	SARG|gb|AEA37904.1|ARO:3003112|lsaC	25.4	197	262	492	6.26e-08	52.0
k141_101726_10	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	57.9	159	160	159	3.63e-59	180
k141_101726_14	SARG|gi|446048013|ref|WP_000125868.1|	39.8	221	251	648	1.07e-38	141
k141_101726_14	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.4	237	251	664	5.15e-20	87.8
k141_101726_14	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	26.6	207	251	528	2.44e-07	50.1
k141_160393_9	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	34.3	210	484	373	2.91e-23	100
k141_160393_21	SARG|gb|ADZ12699.1|ARO:3005091|RanA	34.3	248	348	258	7.85e-38	135
k141_160393_21	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	33.0	221	348	255	1.07e-36	132
k141_160393_21	SARG|gi|895865878|ref|WP_048974758.1|	33.6	220	348	646	1.24e-29	118
k141_1972_2	NCBI|WP_268871842.1|1|1|nimK|nimK||2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimK|AMR|nitroimidazole	33.5	158	158	168	8.71e-11	56.2
k141_56803_7	SARG|gi|895981299|ref|WP_049056431.1|	42.2	218	233	648	7.12e-53	179
k141_56803_7	SARG|gi|823281237|ref|WP_047037467.1|	42.2	218	233	648	7.12e-53	179
k141_56803_7	SARG|gi|895967513|ref|WP_049046752.1|	42.2	218	233	648	7.12e-53	179
k141_56803_7	SARG|gi|779903733|ref|WP_045374054.1|	42.2	218	233	648	7.12e-53	179
k141_56803_7	SARG|gi|823326845|ref|WP_047080664.1|	42.2	218	233	648	1.38e-52	178
k141_56803_7	SARG|Q83LR7	41.3	218	233	648	1.91e-52	178
k141_56803_7	SARG|gi|695793471|ref|WP_032707680.1|	42.7	218	233	648	1.91e-52	178
k141_56803_7	SARG|gi|647325472|ref|WP_025760953.1|	41.3	218	233	648	1.91e-52	178
k141_56803_7	SARG|gi|647323678|ref|WP_025760497.1|	41.3	218	233	648	1.91e-52	178
k141_56803_7	SARG|gi|823302270|ref|WP_047057473.1|	42.2	218	233	648	2.66e-52	177
k141_115210_7	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	31.0	126	207	342	2.28e-11	60.8
k141_115210_7	SARG|gb|AJP77059|ARO:3003670|PEDO-1	29.8	94	207	286	2.83e-08	51.6
k141_115210_7	SARG|gb|WP_122630825.1|ARO:3006873|EAM-1	25.5	145	207	318	1.40e-07	49.7
k141_115210_7	SARG|gb|AJP77071|ARO:3003714|PEDO-2	28.1	96	207	285	1.05e-06	47.0
k141_115210_7	SARG|gb|AAF89148.1|ARO:3004813|GOB-6	30.2	96	207	252	4.23e-06	45.1
k141_115210_7	ResF|blaGOB-6_1_AF189292_1	30.2	96	207	290	4.76e-06	45.1
k141_115210_7	NCBI|WP_069147617.1|1|1|blaGOB-6|blaGOB|hydrolase|2|||subclass_B3_metallo-beta-lactamase_GOB-6|AMR|beta-lactam	30.2	96	207	290	4.76e-06	45.1
k141_115210_7	SARG|EU408351.1.gene26.p01	28.3	138	207	293	4.79e-06	45.1
k141_115210_7	SARG|gb|AAT68576.1|ARO:3004816|GOB-9	30.2	96	207	290	6.42e-06	44.7
k141_115210_7	SARG|gb|AJP77054|ARO:3003716|CPS-1	28.3	99	207	290	6.42e-06	44.7
k141_164543_6	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	21.5	834	805	1024	1.34e-27	119
k141_164543_6	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	21.5	834	805	1024	1.34e-27	119
k141_164543_6	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	21.5	834	805	1024	2.32e-27	118
k141_164543_6	SARG|gb|CAA53189|ARO:3000521|mupA	21.5	834	805	1024	2.32e-27	118
k141_102201_3	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.4	108	517	1197	8.06e-12	67.0
k141_102201_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	26.5	117	517	219	8.36e-08	52.0
k141_102201_3	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.9	104	517	204	9.38e-08	51.6
k141_74202_2	SARG|gi|445996719|ref|WP_000074574.1|	26.5	204	242	309	5.72e-14	68.9
k141_74202_2	SARG|gi|500448961|gb|EOP61695.1|	26.1	203	242	306	1.04e-13	68.2
k141_74202_2	SARG|gi|500465078|gb|EOP76697.1|	26.1	203	242	306	1.04e-13	68.2
k141_74202_2	SARG|YP_001373621	26.0	204	242	318	1.54e-13	67.8
k141_74202_2	SARG|gi|895736250|emb|COF64653.1|	26.0	204	242	309	2.69e-13	67.0
k141_74202_2	SARG|gi|446110087|ref|WP_000187942.1|	26.0	204	242	309	2.69e-13	67.0
k141_74202_2	SARG|gi|445996714|ref|WP_000074569.1|	26.0	204	242	309	2.69e-13	67.0
k141_74202_2	SARG|gi|445996710|ref|WP_000074565.1|	25.5	204	242	309	3.67e-13	66.6
k141_74202_2	SARG|gi|507044560|ref|WP_016115614.1|	27.0	204	242	306	6.67e-13	65.9
k141_74202_2	SARG|gi|447195835|ref|WP_001273091.1|	25.0	204	242	306	1.23e-12	65.1
k141_74202_8	SARG|gb|WP_104671188.1|ARO:3003948|efrA	44.3	440	528	575	4.38e-109	335
k141_74202_8	SARG|gb|AAK76137.1|ARO:3000024|patA	31.8	500	528	564	3.71e-72	239
k141_74202_8	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.5	471	528	582	3.03e-45	166
k141_74202_8	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.5	454	528	574	1.83e-44	164
k141_74202_8	SARG|gb|CDO61516.1|ARO:3003949|efrB	31.1	331	528	362	5.05e-43	155
k141_74202_8	SARG|gb|AAK76136.1|ARO:3000025|patB	27.2	438	528	588	2.40e-39	150
k141_74202_8	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.9	438	528	664	2.12e-38	148
k141_74202_8	SARG|gi|748767925|ref|WP_040019608.1|	31.7	309	528	623	5.31e-38	146
k141_74202_8	SARG|gi|943909899|ref|WP_055545300.1|	39.5	215	528	601	8.14e-38	145
k141_74202_8	SARG|gi|1011969930|ref|WP_062776015.1|	38.6	215	528	601	1.50e-37	145
k141_77471_1	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	63.0	845	974	1162	0.0	1015
k141_77471_1	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	60.8	844	974	1186	0.0	964
k141_77471_1	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	60.8	844	974	1186	0.0	964
k141_77471_12	SARG|ZP_02848503	40.5	215	218	221	2.69e-44	146
k141_77471_12	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.1	229	218	232	4.10e-43	144
k141_77471_12	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.0	228	218	231	5.64e-43	143
k141_77471_12	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.2	217	218	219	5.71e-43	143
k141_77471_12	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	38.7	230	218	235	6.29e-43	143
k141_77471_12	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.3	226	218	232	2.30e-42	142
k141_77471_12	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.3	226	218	232	2.30e-42	142
k141_77471_12	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.7	215	218	219	6.41e-42	140
k141_77471_12	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.7	215	218	220	6.59e-42	140
k141_77471_12	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.7	228	218	232	9.15e-42	140
k141_133130_2	SARG|gb|AAK76136.1|ARO:3000025|patB	33.8	580	607	588	8.77e-105	327
k141_133130_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	34.8	528	607	664	2.76e-97	310
k141_133130_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	46.7	330	607	362	3.81e-90	282
k141_133130_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.9	527	607	582	6.78e-82	267
k141_133130_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.4	588	607	579	1.73e-81	266
k141_133130_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.9	581	607	579	5.64e-77	254
k141_133130_2	SARG|gi|944009777|ref|WP_055601444.1|	28.7	592	607	628	4.91e-73	245
k141_133130_2	SARG|gi|944152509|ref|WP_055644808.1|	28.9	584	607	616	5.32e-73	244
k141_133130_2	SARG|gi|928900436|ref|WP_053931243.1|	29.8	557	607	600	1.02e-72	243
k141_133130_2	SARG|gi|664579989|ref|WP_031094015.1|	29.8	557	607	601	1.04e-72	243
k141_133130_3	SARG|gi|917203192|ref|WP_051809904.1|	51.1	45	57	620	6.82e-10	51.2
k141_133130_3	SARG|gi|926356413|ref|WP_053687351.1|	51.1	45	57	620	6.82e-10	51.2
k141_133130_3	SARG|gi|926345639|ref|WP_053677539.1|	51.1	45	57	620	6.82e-10	51.2
k141_133130_3	SARG|gi|799286378|ref|WP_045936958.1|	51.1	45	57	620	6.82e-10	51.2
k141_133130_3	SARG|gi|917127754|ref|WP_051734466.1|	51.1	45	57	620	6.82e-10	51.2
k141_133130_3	SARG|gi|926376632|ref|WP_053705806.1|	51.1	45	57	620	6.82e-10	51.2
k141_133130_3	SARG|gi|926294973|ref|WP_053631154.1|	51.1	45	57	620	6.82e-10	51.2
k141_133130_3	SARG|gi|772774655|ref|WP_045322518.1|	51.1	45	57	620	6.82e-10	51.2
k141_133130_3	SARG|gi|1033151784|ref|WP_064457526.1|	61.1	36	57	614	1.75e-09	50.1
k141_133130_3	SARG|gi|987887954|ref|WP_060953374.1|	61.1	36	57	614	1.75e-09	50.1
k141_67386_5	SARG|gi|500448961|gb|EOP61695.1|	31.5	222	283	306	5.02e-29	111
k141_67386_5	SARG|ZP_04081918	31.1	222	283	306	9.75e-29	110
k141_67386_5	SARG|gi|500465078|gb|EOP76697.1|	31.5	222	283	306	1.36e-28	110
k141_67386_5	SARG|gi|445996719|ref|WP_000074574.1|	31.1	222	283	309	2.00e-28	109
k141_67386_5	SARG|gi|542061059|gb|ERI11611.1|	30.0	223	283	316	2.26e-28	109
k141_67386_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.8	235	283	664	2.85e-28	112
k141_67386_5	SARG|YP_001373621	31.1	222	283	318	4.53e-28	108
k141_67386_5	SARG|gi|895736250|emb|COF64653.1|	31.1	222	283	309	5.38e-28	108
k141_67386_5	SARG|gi|446110087|ref|WP_000187942.1|	31.1	222	283	309	5.38e-28	108
k141_67386_5	SARG|gi|445996714|ref|WP_000074569.1|	31.1	222	283	309	5.38e-28	108
k141_67386_6	SARG|gi|1016275448|gb|AMX06027.1|	34.0	235	284	646	3.28e-27	109
k141_67386_6	SARG|gi|498115003|ref|WP_010429159.1|	34.0	235	284	646	3.28e-27	109
k141_67386_6	SARG|gi|981224618|ref|WP_059445588.1|	34.0	235	284	646	6.04e-27	108
k141_67386_6	SARG|gi|836585048|ref|WP_047742322.1|	34.0	235	284	646	6.04e-27	108
k141_67386_6	SARG|gi|779956086|ref|WP_045403603.1|	33.6	235	284	646	1.51e-26	107
k141_67386_6	SARG|gi|754493745|ref|WP_041910640.1|	33.6	235	284	646	1.51e-26	107
k141_67386_6	SARG|gi|782756348|ref|WP_045630015.1|	33.6	235	284	646	1.51e-26	107
k141_67386_6	SARG|gi|695748190|ref|WP_032674455.1|	33.6	235	284	646	2.05e-26	107
k141_67386_6	SARG|gi|544824889|ref|WP_021240890.1|	33.6	235	284	646	2.05e-26	107
k141_67386_6	SARG|gi|695731723|ref|WP_032658224.1|	33.6	235	284	646	2.05e-26	107
k141_36178_1	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	32.6	438	431	444	1.04e-52	181
k141_36178_15	SARG|gb|AAV85982.1|ARO:3000535|macB	30.2	427	430	644	4.42e-31	124
k141_36178_15	SARG|gi|487359045|ref|WP_001634240.1|	27.4	430	430	648	9.10e-26	108
k141_36178_15	SARG|gi|485890120|ref|WP_001482667.1|	27.4	430	430	648	9.10e-26	108
k141_36178_15	SARG|gi|446110286|ref|WP_000188141.1|	27.4	430	430	648	1.22e-25	108
k141_36178_15	SARG|gi|487410704|ref|WP_001678420.1|	27.7	430	430	648	1.64e-25	108
k141_36178_15	SARG|gi|585345156|ref|WP_024226778.1|	27.4	430	430	648	2.96e-25	107
k141_36178_15	SARG|gi|485866062|ref|WP_001464282.1|	27.2	430	430	648	3.97e-25	107
k141_36178_15	SARG|gi|976150970|ref|WP_059309182.1|	27.7	430	430	648	3.97e-25	107
k141_36178_15	SARG|gi|490051604|ref|WP_003953942.1|	27.7	430	430	648	3.97e-25	107
k141_36178_15	SARG|gi|1001947541|ref|WP_061357412.1|	27.4	430	430	648	3.97e-25	107
k141_36178_16	SARG|gi|1033064422|ref|WP_064375412.1|	49.1	220	248	648	1.70e-65	213
k141_36178_16	SARG|gi|803568669|ref|WP_046077412.1|	47.7	220	248	648	6.48e-65	212
k141_36178_16	SARG|gi|446110352|ref|WP_000188207.1|	47.7	220	248	648	6.48e-65	212
k141_36178_16	SARG|YP_002382193	47.7	220	248	648	6.48e-65	212
k141_36178_16	SARG|gi|803575554|ref|WP_046081557.1|	47.7	220	248	648	6.48e-65	212
k141_36178_16	SARG|gi|446110351|ref|WP_000188206.1|	47.7	220	248	648	6.48e-65	212
k141_36178_16	SARG|gi|829942568|ref|WP_047368199.1|	48.2	218	248	646	8.77e-65	211
k141_36178_16	SARG|gi|896106549|ref|WP_049136608.1|	48.6	218	248	646	1.23e-64	211
k141_36178_16	SARG|gi|654544841|ref|WP_028012549.1|	48.2	218	248	646	1.71e-64	211
k141_36178_16	SARG|gi|992390012|ref|WP_061077002.1|	47.7	220	248	648	1.77e-64	211
k141_123081_11	SARG|gb|APB03216.1|ARO:3003982|LlmA	63.8	287	287	287	1.10e-148	417
k141_139909_8	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	36.2	265	348	346	3.18e-44	154
k141_139909_8	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	37.8	262	348	356	5.59e-44	154
k141_139909_8	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	37.4	262	348	356	5.59e-44	154
k141_139909_8	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	37.3	260	348	355	2.93e-43	152
k141_139909_8	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	37.3	260	348	355	2.93e-43	152
k141_139909_8	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	37.0	262	348	356	3.00e-43	152
k141_139909_8	SARG|ACM47285	37.3	260	348	363	3.50e-43	152
k141_139909_8	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	32.2	338	348	355	1.12e-42	150
k141_139909_8	SARG|BAE96115	32.2	338	348	355	1.12e-42	150
k141_108558_9	SARG|gi|686432388|ref|WP_031921070.1|	26.4	450	456	451	3.00e-41	151
k141_108558_9	SARG|gi|686155635|ref|WP_031787393.1|	26.2	442	456	451	4.15e-41	151
k141_108558_9	SARG|gi|446573718|ref|WP_000651064.1|	26.0	442	456	451	5.75e-41	150
k141_108558_9	SARG|ZP_03986195	26.2	450	456	451	1.10e-40	150
k141_108558_9	SARG|gi|686448604|ref|WP_031928572.1|	25.4	441	456	451	1.52e-40	149
k141_108558_9	SARG|gi|487138435|ref|WP_001629863.1|	26.4	450	456	451	1.52e-40	149
k141_108558_9	SARG|gi|516415429|ref|WP_017804827.1|	26.2	450	456	451	2.10e-40	149
k141_108558_9	SARG|gi|446573695|ref|WP_000651041.1|	26.2	450	456	451	2.10e-40	149
k141_108558_9	SARG|gi|446573700|ref|WP_000651046.1|	26.2	450	456	451	2.10e-40	149
k141_108558_9	SARG|gi|686408548|ref|WP_031913080.1|	26.0	450	456	451	2.90e-40	149
k141_108558_21	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	47.6	227	234	228	4.84e-67	205
k141_108558_21	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.2	223	234	219	2.32e-60	188
k141_108558_21	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.2	225	234	232	1.58e-58	184
k141_108558_21	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.4	225	234	231	2.18e-58	183
k141_108558_21	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.9	227	234	232	4.49e-58	182
k141_108558_21	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.9	227	234	232	4.49e-58	182
k141_108558_21	CARD|gb|AAG05188.1|ARO:3005068|ParR	41.6	226	234	235	1.12e-56	179
k141_108558_21	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.2	228	234	231	3.98e-56	177
k141_108558_21	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.0	230	234	232	5.81e-56	177
k141_108558_21	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.6	230	234	232	8.21e-56	177
k141_108558_22	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.8	241	478	381	1.91e-28	115
k141_108558_22	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.8	241	478	381	1.91e-28	115
k141_108558_22	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.7	241	478	381	3.17e-25	105
k141_108558_22	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.7	241	478	381	3.17e-25	105
k141_108558_22	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.7	241	478	381	4.30e-25	105
k141_108558_22	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.7	241	478	381	4.30e-25	105
k141_108558_22	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.7	241	478	381	7.93e-25	104
k141_108558_22	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.7	241	478	381	7.93e-25	104
k141_108558_22	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	26.7	243	478	380	1.06e-24	104
k141_108558_22	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.7	243	478	380	1.06e-24	104
k141_139951_22	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	40.3	489	544	533	5.03e-104	322
k141_139951_22	SARG|AF353562.gene.p01	38.5	335	544	369	2.88e-62	207
k141_139951_60	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.0	256	263	255	6.44e-45	150
k141_139951_60	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.9	224	263	579	2.17e-16	77.4
k141_146969_8	SARG|AUI09862.1	45.7	278	271	287	4.02e-79	239
k141_146969_8	SARG|AJ459418.gene.p01	34.0	262	271	263	3.63e-45	152
k141_146969_8	SARG|gi|970263436|ref|WP_058647620.1|	34.0	262	271	263	7.21e-45	151
k141_146969_8	SARG|gi|499290101|ref|WP_010981367.1|	30.0	270	271	283	8.10e-32	117
k141_146969_8	SARG|gi|638947703|ref|WP_024439711.1|	30.1	279	271	271	1.22e-31	117
k141_146969_8	SARG|gi|553729091|ref|WP_023063817.1|	29.7	279	271	271	1.71e-31	116
k141_146969_8	SARG|gi|504199703|ref|WP_014386805.1|	29.3	270	271	271	2.40e-31	116
k141_146969_8	SARG|gi|920213921|ref|WP_052970363.1|	29.7	279	271	271	2.40e-31	116
k141_146969_8	SARG|gi|550552396|ref|WP_022631488.1|	29.7	279	271	271	3.36e-31	115
k141_146969_8	SARG|gi|916164813|ref|WP_050960181.1|	29.2	277	271	271	3.36e-31	115
k141_147025_2	SARG|ZP_04528247	60.6	284	283	279	7.70e-113	325
k141_147025_2	SARG|ZP_03958019	55.7	280	283	317	3.99e-107	312
k141_147025_2	SARG|ZP_03949893	58.0	276	283	288	8.69e-107	310
k141_147025_2	SARG|ZP_04433866	57.6	276	283	288	4.99e-106	308
k141_147025_2	SARG|ZP_03984017	57.2	276	283	288	1.00e-105	308
k141_147025_2	SARG|YP_002929946	58.8	277	283	282	3.32e-105	306
k141_147025_2	SARG|YP_002937728	57.1	280	283	289	1.20e-104	305
k141_147025_2	SARG|ZP_03938934	50.7	280	283	288	6.24e-92	273
k141_147025_2	SARG|ZP_03941859	50.4	280	283	288	2.52e-91	271
k141_147025_2	SARG|ZP_03945515	50.9	279	283	291	3.18e-90	268
k141_147025_3	SARG|gb|CAH14033.1|ARO:3004100|LpeB	25.6	853	1304	1014	3.29e-49	189
k141_147025_3	CARD|gb|ABS43151.1|ARO:3000784|cmeB	24.5	793	1304	1040	2.02e-39	158
k141_147025_3	CARD|gb|AAC75137.1|ARO:3000794|mdtC	24.1	856	1304	1025	1.78e-38	155
k141_147025_3	SARG|gb|AAG05915.1|ARO:3004074|MuxB	23.5	871	1304	1043	1.66e-37	152
k141_147025_3	CARD|gb|AAL14440.1|ARO:3000775|adeB	24.0	851	1304	1035	3.73e-37	151
k141_147025_3	SARG|gb|AAG05914|ARO:3004075|MuxC	23.5	860	1304	1036	3.37e-36	148
k141_147025_3	NCBI|WP_254563251.1|1|1|cmeB_RE|cmeB_RE|efflux|2|FLORFENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_CmeB,_ciprofloxacin_and_phenicol_resistance_type|AMR|multidrug	24.0	805	1304	1039	4.46e-36	147
k141_147025_3	SARG|YP_348488	23.6	860	1304	1043	1.87e-33	139
k141_147025_3	SARG|gi|654933144|ref|WP_028383500.1|	23.1	815	1304	1063	1.92e-33	139
k141_147025_3	SARG|gi|966461601|ref|WP_058493954.1|	22.2	790	1304	1054	4.33e-33	138
k141_39704_27	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	36.1	119	715	633	2.70e-15	78.6
k141_39704_27	SARG|AAX35723	39.3	107	715	665	4.11e-13	71.6
k141_39704_27	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	33.9	109	715	665	4.48e-11	65.1
k141_39704_27	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	35.1	111	715	674	2.36e-10	62.8
k141_39704_27	SARG|gb|BAI83385.1|ARO:3003440|mecB	35.1	111	715	674	2.36e-10	62.8
k141_154050_9	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	29.3	123	296	291	1.33e-08	53.9
k141_154050_12	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	47.3	355	360	361	3.85e-105	312
k141_154050_12	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	47.3	355	360	361	3.85e-105	312
k141_154050_12	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	47.0	355	360	361	3.10e-104	310
k141_154050_12	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	47.0	355	360	361	3.10e-104	310
k141_154050_12	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	51.6	320	360	354	9.96e-104	308
k141_154050_12	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	46.4	364	360	364	1.15e-99	298
k141_154050_12	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	46.2	364	360	364	3.27e-99	297
k141_154050_12	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	49.7	320	360	354	3.83e-98	294
k141_154050_12	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	45.1	355	360	376	1.54e-97	293
k141_154050_12	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	45.1	355	360	376	1.54e-97	293
k141_154050_13	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	84.0	25	26	235	2.62e-11	53.1
k141_154050_13	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	80.0	25	26	232	9.47e-11	51.6
k141_154050_13	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	80.0	25	26	232	9.47e-11	51.6
k141_154050_13	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	80.0	25	26	232	9.47e-11	51.6
k141_154050_13	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	80.0	25	26	232	9.47e-11	51.6
k141_154050_13	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	80.0	25	26	232	9.47e-11	51.6
k141_154050_13	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	76.0	25	26	232	1.75e-09	48.1
k141_154050_13	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	68.0	25	26	233	6.38e-09	46.6
k141_154050_13	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	72.0	25	26	230	2.28e-08	45.1
k141_154050_13	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	72.0	25	26	239	4.43e-08	44.3
k141_57497_23	SARG|gb|CAE00499.1|ARO:3003835|cdeA	40.3	442	444	441	4.45e-108	325
k141_5616_6	SARG|gb|CAE00499.1|ARO:3003835|cdeA	28.2	433	461	441	1.02e-52	182
k141_84817_6	SARG|gb|AAD01868.1|ARO:3002867|dfrF	55.7	158	162	164	5.45e-53	164
k141_84817_6	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	54.4	158	162	164	1.55e-52	163
k141_84817_6	SARG|gb|WP_149100971.1|ARO:3005351|DfrA39	48.4	157	162	165	2.29e-42	137
k141_84817_6	SARG|gb|CAF31623.1|ARO:3005354|dfr22	45.2	157	162	165	7.44e-41	134
k141_84817_6	NCBI|WP_063844370.1|1|1|dfrA22|dfrA22|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA22|AMR|diaminopyrimidine	45.2	157	162	165	2.11e-40	132
k141_84817_6	SARG|AAT45231	44.6	157	162	165	4.24e-40	132
k141_84817_6	NCBI|WP_071846383.1|1|1|dfrA12|dfrA12|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA12|AMR|diaminopyrimidine	45.2	157	162	165	6.01e-40	131
k141_84817_6	SARG|ABJ15828	44.6	157	162	165	6.01e-40	131
k141_84817_6	SARG|gi|771651285|ref|WP_045232968.1|	45.2	157	162	165	6.01e-40	131
k141_84817_6	SARG|BAD77819	44.6	157	162	165	8.51e-40	131
k141_91790_7	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	22.4	321	451	443	3.44e-15	76.3
k141_119868_3	SARG|gb|AAC75089.1|ARO:3003577|ugd	60.0	410	411	388	2.77e-172	486
k141_119868_5	SARG|gb|AAF63432|ARO:3003744|vatF	43.3	60	163	221	1.52e-07	48.1
k141_119868_5	SARG|M58472.1.gene1.p01	52.5	40	163	209	2.36e-06	44.7
k141_33587_10	SARG|L42544.gene.p01	32.6	638	859	651	1.49e-98	320
k141_33587_10	SARG|AAV80410	32.4	638	859	651	2.98e-97	317
k141_33587_10	SARG|YP_002850805	32.4	623	859	652	1.81e-90	298
k141_33587_10	SARG|ZP_02952732	32.4	623	859	652	6.81e-90	297
k141_33587_10	SARG|ZP_02632674	32.4	623	859	660	8.24e-90	297
k141_33587_10	SARG|NP_348076	31.7	624	859	652	2.55e-89	295
k141_33587_10	SARG|L20800.gene.p01	32.3	623	859	652	1.33e-88	293
k141_33587_10	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	30.1	622	859	654	9.27e-79	267
k141_33587_10	SARG|AJ514254.gene.p01	29.2	620	859	640	9.43e-79	266
k141_33587_10	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	30.1	622	859	670	1.31e-78	267
k141_120088_5	SARG|L42544.gene.p01	37.9	190	612	651	3.69e-29	121
k141_120088_5	SARG|AAV80410	37.9	190	612	651	3.69e-29	121
k141_120088_5	SARG|AJ514254.gene.p01	47.7	128	612	640	1.49e-28	119
k141_120088_5	SARG|Q02652	44.4	144	612	639	2.60e-26	112
k141_120088_5	SARG|ABB70054	46.9	130	612	639	1.92e-25	110
k141_120088_5	SARG|ABI81214	46.9	130	612	639	1.92e-25	110
k141_120088_5	SARG|BAB71968	46.9	130	612	639	1.92e-25	110
k141_120088_5	SARG|YP_002738300	46.9	130	612	639	1.92e-25	110
k141_120088_5	SARG|X04388.gene.p01	46.2	130	612	639	2.55e-25	109
k141_120088_5	SARG|ABN11268	28.3	364	612	639	3.39e-25	109
k141_120088_10	SARG|gi|494938585|ref|WP_007664615.1|	41.4	232	901	647	1.18e-40	158
k141_120088_10	SARG|gi|696411918|ref|WP_032982657.1|	41.4	222	901	647	2.83e-40	157
k141_120088_10	SARG|gi|696402390|ref|WP_032974230.1|	41.4	222	901	647	2.83e-40	157
k141_120088_10	SARG|gi|696423952|ref|WP_032993748.1|	41.4	222	901	647	2.83e-40	157
k141_120088_10	SARG|gi|742378414|ref|WP_038857601.1|	41.4	222	901	647	3.79e-40	157
k141_120088_10	SARG|gi|742384718|ref|WP_038863845.1|	41.4	222	901	647	5.08e-40	156
k141_120088_10	SARG|gi|504542119|ref|WP_014729221.1|	41.4	222	901	647	5.08e-40	156
k141_120088_10	SARG|gi|495004199|ref|WP_007730213.1|	41.4	222	901	647	6.79e-40	156
k141_120088_10	SARG|gi|742409107|ref|WP_038888226.1|	41.4	222	901	647	6.79e-40	156
k141_120088_10	SARG|gi|495067432|ref|WP_007792257.1|	40.5	222	901	647	9.09e-40	155
k141_120088_18	SARG|gi|445996710|ref|WP_000074565.1|	34.3	233	295	309	9.24e-32	119
k141_120088_18	SARG|gi|446110087|ref|WP_000187942.1|	33.1	245	295	309	2.51e-31	117
k141_120088_18	SARG|gi|542061059|gb|ERI11611.1|	30.0	307	295	316	2.87e-31	117
k141_120088_18	SARG|gi|895736250|emb|COF64653.1|	33.9	233	295	309	3.50e-31	117
k141_120088_18	SARG|gi|445996714|ref|WP_000074569.1|	33.9	233	295	309	4.87e-31	117
k141_120088_18	SARG|gi|446026113|ref|WP_000103968.1|	33.3	240	295	306	6.41e-31	116
k141_120088_18	SARG|gi|500448961|gb|EOP61695.1|	32.7	245	295	306	8.93e-31	116
k141_120088_18	SARG|gi|507044560|ref|WP_016115614.1|	33.3	240	295	306	8.93e-31	116
k141_120088_18	SARG|gi|445996719|ref|WP_000074574.1|	32.7	245	295	309	1.32e-30	115
k141_120088_18	SARG|gi|500465078|gb|EOP76697.1|	32.2	245	295	306	4.70e-30	114
k141_92107_3	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	26.6	263	297	346	1.60e-19	86.3
k141_78160_11	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	39.2	691	637	703	8.27e-145	436
k141_127354_7	SARG|gb|AAV85982.1|ARO:3000535|macB	36.5	63	63	644	3.43e-10	52.4
k141_162066_2	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	30.4	358	344	366	3.37e-49	167
k141_162066_3	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	34.1	458	457	481	2.68e-86	271
k141_162066_3	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	35.2	460	457	451	3.26e-86	270
k141_162066_3	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	33.1	456	457	451	2.90e-80	254
k141_75280_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.5	222	224	219	7.66e-48	155
k141_75280_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.5	222	224	220	7.89e-48	155
k141_75280_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.5	222	224	220	1.11e-47	155
k141_75280_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.1	222	224	219	6.12e-47	153
k141_75280_1	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.7	226	224	220	2.51e-46	152
k141_75280_1	SARG|ZP_02848503	40.8	223	224	221	1.46e-45	150
k141_75280_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.8	222	224	219	3.48e-43	144
k141_75280_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.9	221	224	228	4.46e-43	144
k141_75280_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.5	228	224	231	8.53e-41	138
k141_75280_1	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.7	228	224	231	1.34e-39	135
k141_75280_3	SARG|gi|505420018|ref|WP_015607120.1|	27.5	247	250	603	7.03e-24	99.0
k141_75280_3	SARG|gb|WP_104671188.1|ARO:3003948|efrA	30.2	235	250	575	3.12e-23	97.1
k141_75280_3	SARG|gi|695842130|ref|WP_032755430.1|	27.1	247	250	603	1.10e-22	95.5
k141_75280_3	SARG|gi|1011969930|ref|WP_062776015.1|	28.3	240	250	601	2.02e-22	94.7
k141_75280_3	SARG|gi|739906046|ref|WP_037756452.1|	28.4	232	250	620	2.06e-22	94.7
k141_75280_3	SARG|gi|944009777|ref|WP_055601444.1|	28.8	243	250	628	3.81e-22	94.0
k141_75280_3	SARG|gi|695865802|ref|WP_032778631.1|	27.1	247	250	605	5.06e-22	93.6
k141_75280_3	SARG|gi|664556405|ref|WP_031071225.1|	26.1	238	250	602	6.85e-22	93.2
k141_75280_3	SARG|gi|516574297|ref|WP_017949361.1|	28.0	232	250	620	6.96e-22	93.2
k141_75280_3	SARG|gi|664244930|ref|WP_030776974.1|	27.6	243	250	601	9.28e-22	92.8
k141_147871_8	SARG|gi|926250866|ref|WP_053589133.1|	29.4	201	235	492	3.79e-16	75.9
k141_147871_8	SARG|gi|951399103|ref|WP_057773891.1|	28.9	201	235	492	3.16e-15	73.2
k141_147871_8	SARG|gi|499132967|ref|WP_010860999.1|	28.9	201	235	492	3.16e-15	73.2
k141_147871_8	SARG|gi|489438834|ref|WP_003344330.1|	29.4	201	235	492	3.16e-15	73.2
k141_147871_8	SARG|gi|938181371|ref|WP_054611487.1|	28.9	201	235	493	5.79e-15	72.4
k141_147871_8	SARG|gi|860350489|ref|WP_048392759.1|	30.6	193	235	493	5.79e-15	72.4
k141_147871_8	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	32.0	194	235	550	6.09e-15	72.4
k141_147871_8	SARG|gi|817536927|ref|WP_046586836.1|	27.6	203	235	492	7.82e-15	72.0
k141_147871_8	SARG|gi|937111451|ref|WP_054550161.1|	30.6	193	235	493	7.83e-15	72.0
k141_147871_8	SARG|gi|924337096|ref|WP_053474708.1|	28.8	198	235	492	1.06e-14	71.6
k141_109481_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.5	510	582	664	1.19e-94	302
k141_109481_2	SARG|gb|AAK76136.1|ARO:3000025|patB	33.5	522	582	588	7.44e-94	298
k141_109481_2	SARG|gi|496018010|ref|WP_008742581.1|	32.6	512	582	623	3.70e-87	281
k141_109481_2	SARG|gi|928900436|ref|WP_053931243.1|	33.0	522	582	600	4.17e-87	281
k141_109481_2	SARG|gi|664579989|ref|WP_031094015.1|	33.0	522	582	601	4.28e-87	281
k141_109481_2	SARG|gi|517347347|ref|WP_018522839.1|	31.9	514	582	601	1.65e-86	279
k141_109481_2	SARG|gi|558888514|ref|WP_023543283.1|	31.3	515	582	615	3.24e-86	279
k141_109481_2	SARG|AF170880.4.gene1.p01	31.3	515	582	615	4.54e-86	278
k141_109481_2	SARG|gi|926294973|ref|WP_053631154.1|	31.7	511	582	620	5.11e-86	278
k141_109481_2	SARG|gi|917229923|ref|WP_051836635.1|	32.1	511	582	620	7.16e-86	278
k141_109481_3	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.2	571	576	575	5.11e-122	370
k141_109481_3	SARG|gb|AAK76137.1|ARO:3000024|patA	32.6	570	576	564	3.70e-97	306
k141_109481_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.3	489	576	664	1.31e-63	219
k141_109481_3	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.2	575	576	579	1.93e-60	209
k141_109481_3	SARG|gb|AAK76136.1|ARO:3000025|patB	28.7	520	576	588	2.29e-60	209
k141_109481_3	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.1	577	576	579	2.68e-60	209
k141_109481_3	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	28.1	581	576	579	3.72e-60	208
k141_109481_3	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	28.5	572	576	579	3.72e-60	208
k141_109481_3	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	28.2	525	576	574	4.70e-60	208
k141_109481_3	SARG|gi|919568551|ref|WP_052871170.1|	27.1	527	576	620	9.94e-57	200
k141_154832_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	25.8	796	880	1024	1.58e-74	263
k141_154832_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.8	796	880	1024	1.58e-74	263
k141_154832_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.8	796	880	1024	5.46e-74	261
k141_154832_1	SARG|gb|CAA53189|ARO:3000521|mupA	25.8	796	880	1024	5.46e-74	261
k141_154832_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	26.3	613	880	1033	5.10e-64	232
k141_154832_1	SARG|gb|AEY83581|ARO:3000510|mupB	26.3	613	880	1033	5.10e-64	232
k141_43974_9	SARG|ACF08831	35.1	134	396	639	1.08e-15	77.8
k141_43974_9	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	36.8	133	396	639	1.91e-15	77.0
k141_43974_10	SARG|NP_348076	27.1	694	706	652	4.87e-73	248
k141_43974_10	SARG|L42544.gene.p01	29.1	671	706	651	6.62e-73	248
k141_43974_10	SARG|AAV80410	28.4	668	706	651	1.28e-72	247
k141_43974_10	SARG|YP_002850805	26.1	682	706	652	4.33e-67	232
k141_43974_10	SARG|ZP_02952732	25.7	682	706	652	1.53e-65	228
k141_43974_10	SARG|ZP_02632674	25.7	682	706	660	1.77e-65	228
k141_43974_10	SARG|L20800.gene.p01	25.7	682	706	652	5.57e-65	226
k141_43974_10	SARG|AJ514254.gene.p01	26.6	693	706	640	1.13e-63	222
k141_43974_10	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.7	672	706	639	7.30e-62	217
k141_43974_10	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.0	684	706	629	1.04e-59	211
k141_43974_24	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.0	275	475	365	4.24e-33	127
k141_43974_24	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.4	299	475	364	1.27e-30	120
k141_43974_24	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.4	299	475	364	1.27e-30	120
k141_43974_24	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.9	264	475	370	6.11e-29	116
k141_43974_24	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.2	202	475	367	8.75e-25	104
k141_43974_24	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.2	202	475	368	8.87e-25	104
k141_43974_24	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.8	263	475	380	4.76e-24	102
k141_43974_24	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.8	263	475	380	4.76e-24	102
k141_43974_24	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.2	235	475	352	1.53e-23	100
k141_43974_24	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.2	235	475	376	2.08e-23	100
k141_43974_25	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.8	219	218	219	1.96e-49	159
k141_43974_25	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.1	207	218	232	9.10e-48	155
k141_43974_25	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.1	207	218	232	9.10e-48	155
k141_43974_25	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.8	217	218	228	4.12e-45	149
k141_43974_25	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.1	230	218	229	4.23e-42	141
k141_43974_25	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.2	223	218	232	5.13e-41	138
k141_43974_25	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	35.7	230	218	235	7.84e-41	138
k141_43974_25	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	38.8	227	218	239	3.46e-40	136
k141_43974_25	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.5	226	218	231	1.11e-39	135
k141_43974_25	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.8	226	218	231	3.11e-39	134
k141_43974_28	SARG|gi|1004359922|gb|AMP42228.1|	27.2	434	605	639	1.41e-26	113
k141_43974_28	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.7	435	605	629	1.79e-25	110
k141_43974_28	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.7	435	605	629	1.79e-25	110
k141_43974_28	ResF|tet(O/W)_3_AM889120_1	26.7	435	605	639	1.84e-25	110
k141_43974_28	ResF|tet(O/W)_4_AM889121_1	26.7	435	605	639	1.84e-25	110
k141_43974_28	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.7	435	605	629	4.21e-25	108
k141_43974_28	ResF|tet(O/W)_5_AM889122_1	26.7	435	605	639	4.34e-25	108
k141_43974_28	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	435	605	629	7.44e-25	108
k141_43974_28	SARG|ABV82118	25.3	435	605	639	7.67e-25	108
k141_43974_28	SARG|AAY62597	27.1	435	605	639	7.67e-25	108
k141_96103_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.8	229	229	232	1.31e-47	155
k141_96103_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.8	229	229	232	1.31e-47	155
k141_96103_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.2	229	229	231	4.05e-46	152
k141_96103_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.2	229	229	231	4.05e-46	152
k141_96103_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.5	228	229	231	9.06e-45	148
k141_96103_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.3	229	229	232	7.39e-44	146
k141_96103_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.3	229	229	231	1.01e-43	145
k141_96103_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	38.5	234	229	235	1.13e-43	145
k141_96103_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.3	229	229	231	1.43e-43	145
k141_96103_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.3	229	229	231	1.43e-43	145
k141_96103_3	CARD|gb|ABD30512.1|ARO:3000839|arlS	33.6	247	447	451	9.98e-36	136
k141_96103_3	CARD|gb|AEX49906.1|ARO:3003583|basS	29.7	276	447	477	3.96e-23	100
k141_96103_3	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.4	289	447	447	1.76e-19	89.4
k141_96103_3	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.4	289	447	447	1.76e-19	89.4
k141_96103_3	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.4	289	447	447	1.76e-19	89.4
k141_96103_3	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.7	292	447	447	3.17e-19	88.6
k141_96103_3	CARD|gb|ADM92606.1|ARO:3000549|adeS	25.5	294	447	361	1.81e-18	85.5
k141_96103_3	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	25.4	252	447	384	2.96e-18	85.1
k141_96103_3	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	25.4	252	447	384	2.96e-18	85.1
k141_96103_3	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	31.4	207	447	454	3.39e-18	85.5
k141_96103_6	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.7	223	229	229	2.44e-58	183
k141_96103_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.7	223	229	232	1.52e-57	181
k141_96103_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.7	223	229	232	1.52e-57	181
k141_96103_6	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	42.9	224	229	231	8.36e-57	179
k141_96103_6	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.9	224	229	231	8.36e-57	179
k141_96103_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.0	226	229	232	8.62e-57	179
k141_96103_6	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.6	221	229	219	1.65e-56	178
k141_96103_6	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.0	227	229	231	4.75e-56	177
k141_96103_6	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	42.9	224	229	233	5.04e-56	177
k141_96103_6	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.0	224	229	231	6.72e-56	177
k141_96103_7	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.1	320	485	451	3.15e-29	118
k141_96103_7	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	28.3	223	485	386	1.47e-19	89.4
k141_96103_7	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	223	485	386	1.47e-19	89.4
k141_96103_7	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	223	485	386	1.47e-19	89.4
k141_96103_7	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	28.3	223	485	386	1.47e-19	89.4
k141_96103_7	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	28.3	223	485	388	3.63e-19	88.2
k141_96103_7	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	223	485	388	3.63e-19	88.2
k141_96103_7	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.8	223	485	382	8.35e-19	87.0
k141_96103_7	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.8	223	485	382	8.35e-19	87.0
k141_96103_7	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.8	223	485	384	8.49e-19	87.0
k141_131124_1	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.4	218	381	467	2.33e-25	105
k141_131124_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	23.2	228	381	370	5.45e-20	89.4
k141_131124_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	29.8	215	381	885	2.43e-19	89.0
k141_131124_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.9	209	381	381	4.13e-18	84.0
k141_131124_1	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.9	209	381	381	4.13e-18	84.0
k141_131124_1	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.2	218	381	381	2.49e-17	81.6
k141_131124_1	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.2	218	381	381	2.49e-17	81.6
k141_131124_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	24.4	209	381	365	3.00e-17	81.3
k141_131124_1	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	26.8	224	381	341	8.70e-11	61.6
k141_165734_3	SARG|ZP_04081918	37.1	313	354	306	9.16e-51	170
k141_165734_3	SARG|gi|507044560|ref|WP_016115614.1|	35.4	314	354	306	1.81e-50	169
k141_165734_3	SARG|gi|445996719|ref|WP_000074574.1|	35.8	313	354	309	1.51e-49	167
k141_165734_3	SARG|gi|488068784|ref|WP_002140181.1|	34.5	310	354	309	2.98e-49	166
k141_165734_3	SARG|gi|445996708|ref|WP_000074563.1|	34.8	310	354	309	8.26e-49	165
k141_165734_3	SARG|gi|507055561|ref|WP_016126482.1|	38.6	246	354	309	8.26e-49	165
k141_165734_3	SARG|gi|488053456|ref|WP_002124853.1|	38.6	246	354	309	8.26e-49	165
k141_165734_3	SARG|gi|488130770|ref|WP_002201978.1|	34.5	310	354	309	8.26e-49	165
k141_165734_3	SARG|gi|507023808|ref|WP_016095885.1|	34.2	310	354	309	8.26e-49	165
k141_165734_3	SARG|gi|445996710|ref|WP_000074565.1|	35.3	312	354	309	8.26e-49	165
k141_16198_10	SARG|AF155139.2.gene5.p01	43.2	95	176	206	1.14e-16	73.2
k141_16198_10	SARG|gi|1028848471|ref|WP_064017434.1|	41.5	94	176	206	4.44e-15	68.9
k141_16198_10	SARG|gi|515720450|ref|WP_017153050.1|	44.1	93	176	210	6.58e-15	68.6
k141_16198_10	SARG|gi|670466162|ref|WP_031414939.1|	40.4	94	176	206	3.23e-14	66.6
k141_120825_18	SARG|gi|1035706844|ref|WP_064548272.1|	40.3	77	947	648	5.34e-09	58.9
k141_120825_31	megares|MEG_7070|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETD_1	36.9	111	305	138	1.13e-16	74.3
k141_13404_4	SARG|gi|851935911|ref|WP_048224705.1|	30.7	313	309	660	4.19e-41	150
k141_13404_4	SARG|gi|489117806|ref|WP_003027650.1|	30.7	313	309	660	7.90e-41	149
k141_13404_4	SARG|gi|851917461|ref|WP_048217311.1|	30.7	313	309	660	1.09e-40	149
k141_13404_4	SARG|gi|696375142|ref|WP_032949690.1|	30.7	313	309	660	1.09e-40	149
k141_13404_4	SARG|gi|851965596|ref|WP_048234849.1|	30.7	313	309	660	1.49e-40	148
k141_13404_4	SARG|gi|1002399350|ref|WP_061382108.1|	30.7	313	309	660	1.49e-40	148
k141_13404_4	SARG|gi|765458296|ref|WP_044714032.1|	30.4	313	309	660	2.05e-40	148
k141_13404_4	SARG|gi|851981245|ref|WP_048240645.1|	30.7	313	309	660	2.05e-40	148
k141_13404_4	SARG|YP_002850217	30.4	313	309	660	2.81e-40	147
k141_13404_4	SARG|gi|851899656|ref|WP_048211088.1|	30.0	310	309	660	3.86e-40	147
k141_13404_7	NCBI|WP_002349981.1|1|1|cfr(B)|cfr(B)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/LINEZOLID/RETAPAMULIN/STREPTOGRAMIN_B/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(B)|AMR|multidrug	35.3	331	351	349	2.62e-54	181
k141_13404_7	SARG|gb|CDF47262.1|ARO:3004649|cfr(B)	35.3	331	351	349	2.62e-54	181
k141_13404_7	SARG|gb|AIX48090.1|ARO:3004599|clcD	35.0	331	351	349	1.02e-53	179
k141_13404_7	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	35.6	334	351	416	2.09e-51	175
k141_13404_7	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	35.0	334	351	379	4.87e-51	173
k141_13404_9	CARD|gb|WKR28567.1|ARO:3007678|IreK	35.2	596	670	718	2.15e-94	306
k141_65490_16	SARG|gi|515720450|ref|WP_017153050.1|	29.2	161	166	210	9.16e-10	54.3
k141_65490_16	SARG|AF155139.2.gene5.p01	38.7	75	166	206	2.16e-08	50.4
k141_65490_16	SARG|gi|1028848471|ref|WP_064017434.1|	33.3	78	166	206	7.68e-08	48.9
k141_65490_16	SARG|gi|670466162|ref|WP_031414939.1|	46.5	71	166	206	2.72e-07	47.4
k141_110109_6	SARG|gb|AAK76137.1|ARO:3000024|patA	33.6	574	595	564	1.25e-96	305
k141_110109_6	SARG|gb|WP_104671188.1|ARO:3003948|efrA	33.7	561	595	575	1.39e-94	300
k141_110109_6	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.2	493	595	664	1.97e-63	219
k141_110109_6	SARG|gb|AAK76136.1|ARO:3000025|patB	28.9	495	595	588	3.43e-61	212
k141_110109_6	SARG|gi|943896259|ref|WP_055534530.1|	38.3	316	595	601	2.76e-56	199
k141_110109_6	SARG|gi|1011969930|ref|WP_062776015.1|	37.3	322	595	601	1.39e-55	197
k141_110109_6	SARG|gi|664244930|ref|WP_030776974.1|	38.0	316	595	601	2.65e-55	196
k141_110109_6	SARG|gi|930482089|ref|WP_054228897.1|	38.2	317	595	599	3.54e-55	196
k141_110109_6	SARG|gi|985844137|ref|WP_060895163.1|	38.2	317	595	599	3.54e-55	196
k141_110109_6	SARG|gi|944470764|ref|WP_055701183.1|	37.7	316	595	601	3.66e-55	196
k141_110109_7	SARG|gb|AAK76136.1|ARO:3000025|patB	32.2	602	641	588	2.26e-95	304
k141_110109_7	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.9	574	641	664	1.25e-84	278
k141_110109_7	SARG|gi|505420018|ref|WP_015607120.1|	30.4	624	641	603	3.71e-80	264
k141_110109_7	SARG|gi|695842130|ref|WP_032755430.1|	30.3	624	641	603	1.41e-79	263
k141_110109_7	SARG|gi|944009777|ref|WP_055601444.1|	30.6	611	641	628	4.85e-79	262
k141_110109_7	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	30.2	620	641	578	8.15e-79	260
k141_110109_7	SARG|gi|662175949|ref|WP_030118884.1|	30.7	602	641	605	1.53e-78	260
k141_110109_7	SARG|gi|663330365|ref|WP_030329892.1|	30.7	602	641	607	2.23e-78	259
k141_110109_7	SARG|gi|664180077|ref|WP_030714054.1|	30.0	623	641	605	2.98e-78	259
k141_110109_7	SARG|gi|497748188|ref|WP_010062372.1|	30.3	611	641	605	4.15e-78	259
k141_37795_2	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	33.1	121	237	232	5.79e-08	50.8
k141_37795_2	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	28.7	164	237	232	1.06e-07	50.1
k141_37795_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	32.2	121	237	232	1.44e-07	49.7
k141_37795_2	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	32.2	121	237	232	1.95e-07	49.3
k141_37795_2	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	32.2	121	237	232	1.95e-07	49.3
k141_37795_9	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	30.2	179	248	494	1.51e-13	68.6
k141_37795_9	SARG|gb|AAK76137.1|ARO:3000024|patA	25.0	220	248	564	1.05e-11	63.2
k141_37795_9	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	185	248	655	3.63e-11	61.6
k141_37795_9	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	185	248	655	3.63e-11	61.6
k141_37795_9	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	185	248	655	2.90e-10	58.9
k141_37795_9	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	185	248	655	3.90e-10	58.5
k141_37795_9	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	185	248	655	3.90e-10	58.5
k141_37795_9	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	185	248	655	3.90e-10	58.5
k141_37795_9	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	185	248	655	3.90e-10	58.5
k141_37795_9	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	185	248	655	3.90e-10	58.5
k141_76172_5	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	32.1	218	233	293	2.71e-36	128
k141_76172_5	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.8	227	233	307	8.19e-23	93.2
k141_76172_5	SARG|gi|446026113|ref|WP_000103968.1|	25.8	221	233	306	3.59e-18	80.5
k141_76172_5	SARG|P42332	24.5	241	233	306	4.62e-17	77.4
k141_76172_5	SARG|gi|507044560|ref|WP_016115614.1|	25.3	221	233	306	4.62e-17	77.4
k141_76172_5	SARG|gi|447195835|ref|WP_001273091.1|	25.0	240	233	306	6.36e-17	77.0
k141_76172_5	SARG|AAD21213	24.5	241	233	306	6.36e-17	77.0
k141_76172_5	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	24.1	241	233	306	1.20e-16	76.3
k141_76172_5	SARG|gi|447195836|ref|WP_001273092.1|	25.0	240	233	306	1.20e-16	76.3
k141_76172_5	SARG|gi|510143239|gb|AGN36970.1|	24.1	241	233	313	1.28e-16	76.3
k141_76172_12	SARG|gi|585358510|ref|WP_024240108.1|	31.1	196	224	648	2.31e-27	108
k141_76172_12	SARG|gi|507044560|ref|WP_016115614.1|	28.3	187	224	306	2.94e-14	69.3
k141_76172_12	SARG|gb|AAK76136.1|ARO:3000025|patB	25.6	207	224	588	7.50e-14	68.9
k141_76172_12	SARG|gi|446026113|ref|WP_000103968.1|	27.8	187	224	306	1.40e-13	67.4
k141_76172_12	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	24.9	209	224	578	6.86e-12	63.2
k141_76172_12	SARG|gb|CDO61516.1|ARO:3003949|efrB	25.9	197	224	362	1.79e-11	61.6
k141_76172_12	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.2	218	224	575	3.37e-10	58.2
k141_76172_12	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.1	183	224	664	2.11e-09	55.8
k141_76172_12	SARG|gb|AAK76137.1|ARO:3000024|patA	25.3	178	224	564	1.62e-08	53.1
k141_76172_12	SARG|gi|1011969930|ref|WP_062776015.1|	24.1	166	224	601	1.31e-07	50.4
k141_16773_1	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	41.9	117	147	164	7.17e-26	95.1
k141_16773_1	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	37.8	148	147	167	8.66e-25	92.4
k141_16773_1	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	42.7	117	147	166	1.48e-22	86.7
k141_16773_1	SARG|CAL48457	41.7	115	147	183	1.56e-22	87.0
k141_16773_1	SARG|CAE53424	42.7	117	147	169	2.24e-22	86.3
k141_16773_1	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	34.2	146	147	164	6.16e-21	82.4
k141_16773_1	ResF|dfrE_1_CP080326_1	35.2	128	147	128	4.98e-18	73.9
k141_16773_1	SARG|gb|ASF80997.1|ARO:3005164|dfrA35	37.1	116	147	170	1.97e-16	70.9
k141_16773_1	SARG|gb|WP_045475347.1|ARO:3005334|DfrA42_TMP	25.6	129	147	177	9.15e-06	42.4
k141_107134_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	45.1	678	644	703	3.45e-170	501
k141_107134_26	SARG|gi|515720450|ref|WP_017153050.1|	35.7	115	188	210	1.70e-14	67.8
k141_107134_26	SARG|AF155139.2.gene5.p01	34.8	115	188	206	3.06e-13	64.3
k141_107134_26	SARG|gi|1028848471|ref|WP_064017434.1|	34.8	115	188	206	8.15e-13	63.2
k141_107134_26	SARG|gi|670466162|ref|WP_031414939.1|	37.4	99	188	206	2.17e-12	62.0
k141_107134_26	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	35.4	99	188	159	8.60e-07	45.8
k141_110794_2	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	38.4	219	254	343	5.16e-50	166
k141_110794_2	SARG|gi|817122037|ref|WP_046494699.1|	27.3	216	254	613	7.55e-17	78.6
k141_110794_2	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	26.6	214	254	528	1.81e-08	53.5
